Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model (Kitty Nose)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03031145
Recruitment Status : Withdrawn (Lack of funding)
First Posted : January 25, 2017
Last Update Posted : December 7, 2017
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of felis domesticus, or cat, extract in e-cigarette users, cigarette smokers, and non-smokers.

Condition or disease Intervention/treatment Phase
Tobacco Smoking Healthy Participants E-cigarette Smokers Biological: Felis Domesticus Phase 1

Detailed Description:

The recent increase in popularity of e-cigarettes for smoking cessation or in combination with conventional cigarettes has let to safety concerns regarding their potential role in respiratory disease. These tobacco alternatives devices were initially perceived as a "safer" alternative to cigarettes and were marketed without much known about their health effects. Increasing evidence that while they contain fewer toxins and carcinogens than conventional cigarettes, they do involve delivery of ultrafine particles to the lower airways and can contain heavy metals and other chemicals. Tobacco Smoke may augment allergic inflammation resulting from allergic rhinitis and/or asthma. Animal models of allergic asthma demonstrate aggravation of allergen -induced airway inflammation following inhalation of e-cig cartridge solution, with increased airway eosinophil infiltration, production of Th2 cytokines, and airway hyperresponsivness. In vitro studies in human tissues have demonstrated pro-inflammatory responses in a similar way as tobacco smoke, yet a head-to-head comparison of the effects of these two exposures has not been performed in humans.

Use of tobacco products remains a pervasive problem in our society and around the world, with significant impact on respiratory health and quality of life. With the emergence of new non-tobacco based nicotine products like e-cigarettes, it is important to understand the impact these substances have on respiratory health and disease. The aim o f this study is to study the impact of these products on allergic inflammation in cat allergic subjects who already routinely use e-cigarettes and to compare their response to those of cigarette smokers and non-smokers. A thorough understanding of the potential health impacts of tobacco alternative substances in seeded, especially given the rising popularity of such products with adolescents and young adults to whom these substances have particular appeals given the purported safety: and variety of flavors to chose from.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model
Actual Study Start Date : April 3, 2017
Actual Primary Completion Date : December 4, 2017
Actual Study Completion Date : December 4, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking
Drug Information available for: Cat Hair

Arm Intervention/treatment
Active Comparator: Felis Domesticus treated Non-smoker Biological: Felis Domesticus
Nasal Administration of Felis Domesticus
Other Name: Cat Allergen

Active Comparator: Felis Domesticus treated E-cigarette smoker Biological: Felis Domesticus
Nasal Administration of Felis Domesticus
Other Name: Cat Allergen

Active Comparator: Felis Domesticus treated Cigarette smoker Biological: Felis Domesticus
Nasal Administration of Felis Domesticus
Other Name: Cat Allergen




Primary Outcome Measures :
  1. Change in eosinophils/mL in nasal lavage fluid (NLF) [ Time Frame: Pre- and 4 hours post- nasal allergen challenge ]
    NLF will be collected immediately prior to administration of the nasal allergen challenge. 4 hours after administration of a bolus provocative dose of allergen (determined at screening day visit nasal allergen challenge), NLF will be collected. Pre- and 4 hours post-challenge NLF will be analyzed for cellularity. Values will be compared across e-cigarette smokers, tobacco cigarette smokers, and non-smokers.


Secondary Outcome Measures :
  1. Nasal lavage fluid cytokines [ Time Frame: Pre- and 4 hours post- nasal allergen challenge ]
    NLF will be collected immediately prior to administration of the nasal allergen challenge, and 4 hours post-nasal allergen challenge. Cytokine levels will be quantified with commercially available ELISAs.

  2. Nasal epithelial cell messenger ribonucleic acid (mRNA) [ Time Frame: Baseline (within two months of nasal allergen challenge) and 4 hours post- nasal allergen challenge ]
    Nasal epithelial cell biopsies will be collected at baseline (within two months of nasal allergen challenge), and 4 hours post-nasal allergen challenge. Gene expression changes will be quantified using qRT-PCR.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and females age 18-50 years
  2. Specific allergy to cat hair Felis domesticus confirmed by positive immediate skin test response
  3. Subjects may be enrolled with mild asthma if a Forced Expiratory Volume in 1 second (FEV1) of at least 80% of predicted and a Forced Expiratory Volume in 1 second to Forced Vital Capacity (FVC) ratio (FEV1/FVC ratio) of at least .75 (without use of bronchodilator medications for 12 hours), consistent with lung function of persons with mild episodic or mild persistent asthma is demonstrated. For the purpose of this protocol, an asthmatic individual will be defined as having a) positive methacholine challenge with a provocative concentration of methacholine producing a 20% fall in FEV1 (PC20 methacholine) with less than or equal to 10 mg/ml; OR b) physician diagnosed asthma with symptoms and chronic daily therapy consistent with the mild asthma
  4. Ability to withhold antihistamine medications for one week prior to baseline and allergen challenge visits.
  5. Subjects must be able and willing to give informed consent.
  6. Subjects will be classified as tobacco smokers, e-cigarette users, or non-smokers

Exclusion Criteria:

  1. Any chronic medical condition considered by the PI as a contraindication to the allergen challenge study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, bleeding disorder, or chronic thyroid disease.
  2. Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
  3. Use of systemic steroid therapy within the preceding 12 months for treatment of an asthma exacerbation.
  4. Use of inhaled or nasal steroids, cromolyn or leukotriene receptor antagonists (Montelukast or Zafirkulast) within the past month (except for use of cromolyn exclusively prior to exercise).
  5. Use of allergen immunotherapy.
  6. Use of daily theophylline within the past month.
  7. Use of nasal medications that might alter the response to nasal allergen challenge including anti-inflammatory and anti-histamine agents within one week of challenge.
  8. Inability to withhold inhaled or oral bronchodilator medications for 12 hours prior to allergen challenge.
  9. Pregnancy or nursing a baby.
  10. Women of child-bearing age who are not using dependable contraception (such as birth control pills, IUD, estrogen patches) or who are not completely abstinent.
  11. Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  12. Exacerbation of asthma more than 2x/week which would be characteristic of a person with moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  13. Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
  14. Viral upper respiratory tract infection within 4 weeks of challenge.
  15. Any acute infection requiring antibiotics within 4 weeks of challenge.
  16. Participating in an allergen inhalation study within 2 weeks of this challenge or use of any investigational agent within the last 30 days.
  17. Use of tricyclic antidepressants or beta-blockers.
  18. Use of MAO inhibitors or any medications known to interfere with the treatment of anaphylaxis.
  19. Subjects with a history of immunologic disease or undergoing immune suppression for cancer or other diseases.
  20. Subjects with acute inflammatory conditions in the nose or paranasal sinuses, such as sinusitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03031145


Locations
Layout table for location information
United States, North Carolina
UNC Center for Environmental Medicine, Asthma and Lung Biology
Chapel Hill, North Carolina, United States, 27599-7310
Sponsors and Collaborators
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Michelle Hernandez, MD University of North Carolina
Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03031145    
Other Study ID Numbers: 16-1686
First Posted: January 25, 2017    Key Record Dates
Last Update Posted: December 7, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes